company background image
NRBO logo

NeuroBo Pharmaceuticals NasdaqCM:NRBO Stock Report

Last Price

US$4.30

Market Cap

US$21.3m

7D

4.6%

1Y

-24.3%

Updated

26 Mar, 2024

Data

Company Financials +

NeuroBo Pharmaceuticals, Inc.

NasdaqCM:NRBO Stock Report

Market Cap: US$21.3m

NRBO Stock Overview

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases.

NRBO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NeuroBo Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NeuroBo Pharmaceuticals
Historical stock prices
Current Share PriceUS$4.30
52 Week HighUS$7.60
52 Week LowUS$2.89
Beta-0.43
1 Month Change-18.87%
3 Month Change30.30%
1 Year Change-24.30%
3 Year Change-99.58%
5 Year Changen/a
Change since IPO-99.80%

Recent News & Updates

Recent updates

NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Sep 29

Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely

Sep 14
Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely

NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split

Sep 12

NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases

Nov 25

NeuroBo on track to post a record gain after announcing a special meeting

Jun 14

NeuroBo Pharmaceuticals rallies on ANA Therapeutics acquisition

Jan 06

Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like

Dec 21
Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like

NeuroBo Pharmaceuticals EPS misses by $0.02

Nov 13

Shareholder Returns

NRBOUS BiotechsUS Market
7D4.6%-0.5%0.6%
1Y-24.3%9.6%29.5%

Return vs Industry: NRBO underperformed the US Biotechs industry which returned 10.2% over the past year.

Return vs Market: NRBO underperformed the US Market which returned 29.8% over the past year.

Price Volatility

Is NRBO's price volatile compared to industry and market?
NRBO volatility
NRBO Average Weekly Movement23.9%
Biotechs Industry Average Movement11.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: NRBO's share price has been volatile over the past 3 months.

Volatility Over Time: NRBO's weekly volatility has increased from 16% to 24% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20142Hyung-Heon Kimhttps://www.neurobopharma.com

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001.

NeuroBo Pharmaceuticals, Inc. Fundamentals Summary

How do NeuroBo Pharmaceuticals's earnings and revenue compare to its market cap?
NRBO fundamental statistics
Market capUS$21.27m
Earnings (TTM)-US$11.83m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NRBO income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$11.83m
Earnings-US$11.83m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.44
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NRBO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.